3 results
Primary: To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Secondary: Long term safety and other efficacy parameters.
Primary:To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatmentSecondary:To assess the efficacy (exacerbations), FEV1 3h post dose, asthma symptoms, safety and tolerability.
To evaluate the safety and performance of the Neovasc Tiara MitralTranscatheter Heart Valve with the Tiara Transapical Delivery System.Data collected in this clinical study will include 30-day safety and performance ofthe device and delivery system…